AnGes Inc - Company Profile
Powered by 
All the data and insights you need on AnGes Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AnGes Inc Strategy Report
- Understand AnGes Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
AnGes Inc (AnGes) is a biopharmaceutical company, which discovers and develops gene and nucleotide-based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. It has two main projects under development, namely, a hepatocyte growth factor (HGF) plasmid, which is a genetic medicine that improves blood circulation by regenerating blood vessels and NF-KB decoy oligonucleotide. It also develops therapeutic vaccine projects including CIN (cervical intraepithelial neoplasia) therapeutic vaccines. The company has operations in the US and Japan. AnGes is headquartered in Ibaraki, Osaka, Japan.
Headquarters
Japan
Address
Saito Bio-Incubator, 7-7-15, Saito-Asagi, Ibaraki-Shi, Osaka, 567-0085
Website
www.anges.co.jp
Telephone
81 3 57302641
No of Employees
145
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4563 (TYO)
Revenue (2022)
$1.1M
128.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
49.5%
(2022 vs 2021)
Market Cap*
$68.0M
Net Profit Margin (2022)
XYZ
77.8%
(2022 vs 2021)
* As of and is in US$
AnGes Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| HGF Plasmid (BeperminogenePerplasmid): |
| Arteriosclerosis Obliterans with Lower Limb Ulcer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In July, the company established Genetic Testing technology at the AnGes Clinical Research Laboratory. |
| 2023 | Contracts/Agreements | In March, the company and Shionogi & Co Ltd entered into an agreement for the development of NF-κB decoy oligo DNA for the treatment of chronic discogenic low back pain in Japan. |
| 2022 | Financing Agreements | In December, the company announced to invest US$2 million in Vasomune Therapeutics. |
Competitor Comparison
| Key Parameters | AnGes Inc | Takara Bio Inc | Fuso Pharmaceutical Industries Ltd | Kolon Life Science Inc | Kidswell Bio Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | South Korea | Japan |
| City | Ibaraki-Shi | Kusatsu-Shi | Osaka-Shi | Seoul | Chuo-Ku |
| State/Province | Osaka | Shiga | Osaka | - | Tokyo |
| No. of Employees | 145 | 1,793 | 1,314 | 432 | 41 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ei Yamada, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2002 | - |
| Norikazu Eiki | Director | Non Executive Board | 2014 | - |
| Koichi Ando | Director | Non Executive Board | 2021 | - |
| Kimiko Murofushi | Director | Non Executive Board | - | - |
| Junichi Komamura | Director | Non Executive Board | 2012 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward